grant
A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancer
Organization NORTHWESTERN UNIVERSITYLocation CHICAGO, UNITED STATESPosted 12 Jul 2024Deadline 30 Jun 2029
NIHUS FederalResearch GrantFY202521+ years oldAddressAdultAdult HumanAffectAffinityAmerican maleAmerican manAmerican menAttentionB lymphoma Mo MLV insertionBMI1BMI1 geneBindingBiologicalBiological MarkersBrill-Symmers DiseaseCancer CauseCancer EtiologyCancer GenesCancer PatientCancer-Promoting GeneCancersCell BodyCellsCessation of lifeChromatinChromosomal InstabilityChromosome InstabilityClinicalComplexCore ProteinDNADNA DamageDNA Damage RepairDNA InjuryDNA RepairDataDeathDefectDeoxyribonucleic AcidDevelopmentDiagnosisDrug resistanceDrugsEarly DiagnosisEarly treatmentEnhancersEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpithelioid Cell SarcomaEpithelioid SarcomasFollicle Center LymphomaFollicular LymphomaFollicular Non-Hodgkin's LymphomaFutureGATA binding protein 4GATA4GATA4 geneGATA4 transcription factorGene Down-RegulationGene ExpressionGene InactivationGene SilencingGene TranscriptionGeneHomologGeneralized GrowthGenetic TranscriptionGiant Follicular LymphomaGrowthHeterograftHeterologous TransplantationHistone H3Histone-Lysine MethyltransferaseHistone-Lysine N-MethyltransferaseHomologHomologous GeneHomologueL-LysineLysineMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMeasuresMediatingMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Prostate CancerMetastatic TumorMethylationMiceMice MammalsModificationMolecular InteractionMurineMusNeoplasm MetastasisNodular LymphomaOncogenesOncogenicOutcomePARP InhibitorPARP PolymerasePARP proteinPARP-1 inhibitorPARPiPARSPatientsPharmaceutical PreparationsPlayPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) PolymerasesPoly(ADP-ribose) polymerase 1 inhibitorPoly(ADPribose) PolymerasePolycombProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate Carcinoma MetastaticProstate carcinomaProstate malignancyProstatic carcinomaProtein Lysine MethyltransferaseProtein Methylase IIIProtein Methyltransferase IIIProteinsRNA ExpressionRegulationReportingRepressionResistanceResistance developmentResistant developmentRoleSTAT3STAT3 geneSecondary NeoplasmSecondary TumorTestingTherapeuticTissue GrowthTranscriptTranscriptionTranscription RepressionTranscriptional ControlTranscriptional RegulationTransforming GenesTreatment EfficacyU.S. MalesUS MenUS maleUnited StatesUnscheduled DNA SynthesisWorkXenograftXenograft procedureXenotransplantationadulthoodadvanced prostate cancerbio-markersbiologicbiologic markerbiomarkercancer initiationcancer metastasiscancer progressioncancer typecarcinoma prostatic cancercofactorcombinatorialdesigndesigningdeveloping resistancedevelopmentaldrug resistantdrug/agentearly detectionearly therapyeffective therapyeffective treatmentepigeneticallygain of functiongain of function mutationgene locusgene repressiongenetic locusgenomic locationgenomic locushistone H3 methyltransferasehistone methylasehistone methylationhistone methyltransferasehomologous recombination deficiencyhomologous recombination repair deficiencyinhibitorinsightintervention efficacymales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmalignancymenmen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmetabolism measurementmetabolomicsmetabonomicsneoplasm progressionneoplasm/cancerneoplastic progressionnovelontogenyoverexpressoverexpressionpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespharmacologicpoly ADP polymerasepoly ADP ribose synthetaseprogenitor cell maintenanceprogenitor maintenanceprostate cancer cellprostate cancer modelprostate cancer progressionprostate cancer treatmentprostate tumor cellprostate tumor modelprotein H(3)protein H3recruitrefractory cancerresistance to Drugresistance to therapyresistantresistant cancerresistant to Drugresistant to therapyresponseside effectsocial rolestem cell maintenancetherapeutic efficacytherapeutic resistancetherapeutic targettherapeutically effectivetherapy efficacytherapy resistanttranscriptional silencingtreatment resistancetumortumor cell metastasistumor progressiontumor xenograftxeno-transplantxeno-transplantation
Description preview
Prostate cancer is the leading cause of cancer-related deaths in American men. It is estimated that each
year more than 180,000 new prostate cancer patients will be diagnosed, and approximately 26,000 patients in
the United States will die, primarily due to metastasis. This occurs despite advances in early detection and
treatment. The available…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click